Blueprint Medicines
Blueprint Medicines is a biopharmaceutical company that develops and commercializes innovative therapies, including the approved medicine AYVAKIT/AYVAKYT, focusing on allergy/inflammation and oncology/hematology.
Services
Blueprint Medicines provides innovative therapies aimed at tackling the root causes of disease. The company commercializes AYVAKIT/AYVAKYT (avapritinib) in the U.S. and Europe, targeting specific disease areas including allergy/inflammation and oncology/hematology. Additionally, Blueprint Medicines offers a patient support program called YourBlueprint in the U.S. and provides early access programs for investigational therapies.
Products
Blueprint Medicines' key product is AYVAKIT/AYVAKYT (avapritinib), which is commercialized in the U.S. and Europe. The company is focused on developing and commercializing innovative therapies that target the root causes of various diseases. Their product portfolio benefits from collaborations and licensing agreements aimed at enhancing their range of offerings.
Scientific Approach
Blueprint Medicines uses a modality-agnostic drug discovery approach, emphasizing advanced scientific platforms including targeted protein degradation and AI technologies. The company has a track record of R&D success in developing transformative medicines. This approach underscores the company’s commitment to utilizing cutting-edge science for innovative therapeutic solutions.
Global Presence
Blueprint Medicines operates on a global scale, with a significant presence in the U.S. and Europe. The company's international operations ensure their innovative therapies are accessible to a wider patient population, aligning with their mission to target the root causes of disease through effective medical solutions.